by TractManager | Mar 31, 2023 | Emerging Technology Report
Lenire is a bimodal neuromodulation device combining sound and transmucosal electrical tongue stimulation to temporarily relieve the symptoms of tinnitus in patients ≥ 18 years of age with at least moderate tinnitus. Lenire therapy is intended to be self-administered...
by TractManager | Mar 27, 2023 | Emerging Technology Report
Etranacogene dezaparvovec (Hemgenix; formerly AMT-061) is an adeno-associated virus vector-based gene therapy indicated for the treatment of adults with hemophilia B (congenital factor IX deficiency) who currently use factor IX prophylaxis therapy, have current or...
by TractManager | Mar 24, 2023 | Molecular Test Assessment
This report evaluates the clinical validity and clinical utility of the Cologuard test (Exact Sciences Corp.).If you have a Hayes login, click here to view the full report on the Knowledge Center.
by TractManager | Mar 17, 2023 | Emerging Technology Report
Zavegepant is an intranasal novel small-molecule, calcitonin gene-related peptide (CGRP) receptor antagonist indicated for the acute treatment of migraine with or without aura in adults.If you have a Hayes login, click here to view the full report on the Knowledge...
by TractManager | Mar 16, 2023 | Emerging Technology Report
Omecamtiv mecarbil is a first-in-class oral cardiac myosin activator under investigation for the treatment of heart failure with reduced ejection fraction (HFrEF).If you have a Hayes login, click here to view the full report on the Knowledge Center.
Recent Comments